Unichem Laboratories growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+4.3%+23.8%+26.9%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−30.5%+164.2%+320.1%
−57.9%+1,179.8%+91.8%
+83.9%+295.1%+65.2%
+83.9%+295.1%+65.1%
+4.7%+12.6%−0.7%
+10.9%+3.7%−3.0%
+151.9%−142.1%+119.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

UNICHEMLAB₹488.80

Unichem Laboratories Limited

· Pharma & Health
₹ CrorePeersGUFICBIORPGLIFEGUJTHEMSMSPHARMAORCHPHARMAINDSWFTLABSOLARAFDCMcap ₹3,441 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+26.9+23.8+4.3—
EBITDA Growth—+320.1+164.2-30.5—
EBIT Growth—+91.8+1,179.8-57.9—
Net Income Growth—+65.2+295.1+83.9—
EPS Growth—+65.1+295.1+83.9—
Total Assets Growth—-0.7+12.6+4.7—
Total Equity Growth—-3.0+3.7+10.9—
Cash from Operations Growth—+119.6-142.1+151.9—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.